FTC Set To Take Enforcement Action Against Drugmakers Over Orange Book Patent Listings
Executive Summary
Merger reviews could take into account sponsor's Orange Book behavior. FTC's statement does not detail what would make a patent listing 'improper' but the precedents from court cases against various sponsors should offer industry some guideposts.
You may also be interested in...
FTC’s Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement
Commission pursued merger challenge to halt pharma practices it believes can stifle competition and keep drug prices high. Other large biopharma transactions may face similar challenges as FTC pursues its new merger program.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.
Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims
Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange Book because it is directed to systems rather than a method of using the drug, court rules, agreeing with FTC’s analysis.